Gilead Agrees to Pay $1.275 Billion Upfront for Oral Peptide Program
Gilead’s deal for a Phase 1 oral peptide program highlights developers including Entera, which is approaching Phase 3 in osteoporosis.
Gilead’s deal for a Phase 1 oral peptide program highlights developers including Entera, which is approaching Phase 3 in osteoporosis.